Comparison of the efficacy of oral Trigonella foenum-graecum seed extract and placebo in the treatment of none alcoholic fatty liver disease

Shiraz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•the level of ALT and AST greater than 1.5 and less than 10 times normal level; Ultrasound evidence confirm fatty liver disease; age between 18-70 years old; negative pregnancy test for women in reproductive age (up to two weeks prior to the study); negative for hepatitis B and C; BMI: 18.5 to 40; sign the consent form.
•Exclusion criteria: history of more than one unit of alcohol consumption (one value for the Spirits (vodka; whiskey); Wine and Beer are respectively 30-45 cc; 120-150 cc and 360 cc.); fatty liver controller medications; Glucose lowering drugs; Cholesterol lowering drugs; Hypotensive drugs; consumption of vitamin E; taking coenzyme Q10; administration of corticosteroids & glucocorticoids; thyroxin administration; administration of drugs that cause fatty liver; diabetes (type 1 and 2); history of cancer in the past; hepatocellular carcinoma; renal failure (creatinine> 1.5 x ULN); chronic pancreatitis; cirrhosis; uncontrolled hypertension (above 180 mm Hg systolic blood pressure); heart disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis (alkaline phosphatase levels greater than 3 times normal); Wilson's disease; alpha-1 antitrypsin deficiency and coronary artery disease; symptoms of hypothyroidism; hyperthyroidism; disorders of the hypothalamic – pituitary; liver transplantation; pregnant or lactating women; and those who cannot use contraceptives.

发起方